zoledronic acid has been researched along with Nephrotic Syndrome in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirschberg, R | 1 |
| McKenna, KE; Morris, TC; Ramadan, KM | 1 |
| Amico, P; Bodmer, M; Haschke, M; Krähenbühl, S; Kummer, O; Mayr, M; Mihatsch, MJ | 1 |
1 review(s) available for zoledronic acid and Nephrotic Syndrome
| Article | Year |
|---|---|
Renal complications from bisphosphonate treatment.
Topics: Acute Kidney Injury; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Kidney; Kidney Diseases; Nephrotic Syndrome; Pamidronate; Risk Factors; Zoledronic Acid | 2012 |
2 other study(ies) available for zoledronic acid and Nephrotic Syndrome
| Article | Year |
|---|---|
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Clarithromycin; Dexamethasone; Diphosphonates; Glomerulonephritis; Humans; Idarubicin; Imidazoles; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Nephrotic Syndrome; Pamidronate; Protein Synthesis Inhibitors; Pyrazines; Skin Neoplasms; Thalidomide; Zoledronic Acid | 2006 |
Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Glomerulosclerosis, Focal Segmental; Humans; Imidazoles; Kidney; Male; Multiple Myeloma; Nephrotic Syndrome; Time Factors; Treatment Outcome; Zoledronic Acid | 2007 |